STZ-Induced Diabetes

Streptozotocin (STZ) is a chemical used for the destruction of insulin-producing cells and for the generation of Type 1 Diabetes phenotypes in mice. The Jackson Laboratory has extensive experience creating a variety of STZ-induced Diabetes models to facilitate your metabolic research.

Request a Quote

Key benefits

  • Protocols designed and tested by JAX scientists
  • STZ-treated immunodeficient mice are ideal preclinical models for testing human cellular therapies for diabetes
  • Alternative diabetes models using NSGC57BL/6J, and NOD scid strains
  • JAX experts handle and properly dispose of harmful streptozotocin, including byproducts found in mouse excretions
  • Diabetes modeling can be integrated with Efficacy Testing Services and histology services, as needed

Capabilities

  • Standard protocols of streptozotocin (STZ) injections are used to induce diabetes in NSGC57BL/6J, or NOD scid males
  • Customizable diabetes models using other JAX strains, different STZ doses, and more options, after our feasibility assessment   
  • Each injected mouse is periodically weighed, glucose levels measured, recorded, and shipped with your research cohorts
  • Only diabetic mice with non-fasted blood glucose levels of at least 250 mg/dl are shipped

Get started with our STZ-induced Diabetes quote form.

STZ Induction Statistics

NSG males (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

  • 97% of mice with glucose above 250 mg/dl
  • 94% of mice with glucose above 300 mg/dl
  • Average glucose: 456 mg/dl

Additional phenotypic data from STZ-induced NSG diabetic mice are available here.

B6 males C57BL/6J)

  • 90% of mice with glucose above 250 mg/dl
  • 82% of mice with glucose above 300 mg/dl
  • Average glucose: 379 mg/dl

Pricing, ordering, and other frequently asked questions